CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE

Their core work

CHU Grenoble is a major French university hospital that contributes clinical expertise and patient data to European research consortia, particularly in neuroscience and regenerative medicine. Their core strength lies at the intersection of clinical medicine and computational neuroscience — they provide real-world medical context to large-scale brain research initiatives like the Human Brain Project. They also run clinical trials in stem cell therapy, organ transplantation, and biomechanical diagnostics, bridging laboratory discoveries to bedside applications.

What they specialise in

How they've shifted over time

In 2015-2018, CHU Grenoble balanced two tracks: regenerative medicine (stem cell stroke therapy, cell-based implants) and early involvement in the Human Brain Project's brain mapping and simulation work. From 2019 onward, the neuroscience infrastructure work intensified — HBP SGA2 and SGA3, EBRAINS platform, neuromorphic computing — while new clinical interests emerged in transplant immunology (TTV GUIDE TX) and AI-driven clinical knowledge (KATY). The regenerative medicine thread faded as computational neuroscience and digital health became dominant.

CHU Grenoble is moving toward data-driven clinical neuroscience and AI-assisted medicine, making them a strong partner for projects combining clinical datasets with computational tools.

How they like to work

CHU Grenoble exclusively joins projects as a participant — they have never coordinated an H2020 project, which is typical for university hospitals that contribute clinical expertise rather than driving research agendas. They operate in large consortia (264 unique partners across 29 countries), reflecting their role in flagship initiatives like the Human Brain Project. Their modest per-project funding (averaging ~EUR 150K) confirms they serve as specialist clinical contributors rather than lead research performers.

With 264 unique consortium partners across 29 countries, CHU Grenoble has an exceptionally wide network, largely inherited from the massive Human Brain Project consortia. This gives them connections across neuroscience, computing, and clinical research communities throughout Europe.

What sets them apart

CHU Grenoble occupies a rare niche: a practicing hospital embedded in Europe's largest brain research initiative. While many HBP partners are computer science labs or neuroscience institutes, CHU brings actual clinical neurology experience — patient cohorts, imaging data, and trial infrastructure. For consortium builders, they offer the credibility of a major French teaching hospital combined with deep familiarity with large-scale EU research infrastructure projects.

Highlights from their portfolio

• HBP SGA3
  The flagship Human Brain Project's third phase — CHU's longest-running commitment (2020-2023) contributing clinical neuroscience to the EBRAINS research infrastructure.
• Phys2BioMed
  Their highest-funded project (EUR 274,802) exploring biomechanical tools for early cancer diagnosis — an unusual cross-disciplinary move for a neuroscience-focused hospital.
• RESSTORE
  A landmark European clinical trial testing stem cell therapy for stroke recovery, directly aligned with CHU's clinical mission in brain repair.